APOA1 and intrahepatic cholangiocarcinoma: Additionally, pretreatment levels of ApoA1 are predicting favorable outcomes in patients undergoing anti-PD1 therapy for metastatic colorectal cancer, intrahepatic cholangiocarcinoma, and nasopharyngeal carcinoma (43–45).